Systems, apparatus and methods for sealing perivalvular leaks

• US 9,737,399 B2
• Filed: 09/11/2014
• Issued: 08/22/2017
• Est. Priority Date: 09/11/2013
• Status: Active Grant

• Current Assignee: Cormatrix Cardiovascular, Inc.
• Original Assignee: Cormatrix Cardiovascular, Inc.
• Inventors: Matheny, Robert G
• Primary Examiner(s): SCHILLINGER, ANN M
• Application Number:
  US14/483,557
• Publication Number:
  US 20150073548A1
• Time in Patent Office: 1,076 Days
• CPC Class Codes: A61F 2/2412 with soft flexible valve members, e.g. tissue valves shaped like natural valves check valves with flexible valve members in general F16K15/14
• CPC Class Codes: A61F 2/2463 Implants forming part of the valve leaflets
• CPC Class Codes: A61F 2250/0069 Sealing means

Abstract

An expandable member that is configured to engage an interior region of a prosthetic valve and capable of transitioning from a pre-deployment configuration at a pre-deployment temperature, where the expandable member is capable of being positioned in the valve at an interior valve region when the valve is disposed in a cardiovascular structure, to a post-deployment configuration when the expandable member is subjected to cardiovascular tissue temperature, where an outer surface region of the valve proximate the interior valve region is placed in intimate contact with host cardiovascular tissue of the cardiovascular structure at a first position and seals perivalvular leaks present at the first cardiovascular structure position.

Claims

1. A perivalvular leak sealing apparatus, comprising:

a two-stage perivalvular leak abatement structure comprising a biological leak abatement component and a physiomechanical leak abatement component,

said two-stage leak abatement structure comprising a prosthetic cardiovascular tissue valve comprising an interior valve region and an outer surface region, said prosthetic cardiovascular tissue valve being configured to be positioned proximate a cardiovascular valve structure,

said prosthetic cardiovascular tissue valve comprising first acellular extracellular matrix (ECM) from a first mammalian tissue source, said first ECM defining said biological leak sealing component; and

a remodelable, expandable member configured to engage said interior valve region of said prosthetic cardiovascular tissue valve, said expandable member comprising an ECM composition comprising second acellular ECM from a second mammalian tissue source and a HMG-CoA reductase inhibitor selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin,

said expandable member further comprising a flexible, porous structure configured to expand upon exposure to and absorption of a bodily fluid,

said expandable member defining said physiomechanical leak abatement component,

said physiomechanical leak abatement component being configured to transition from a pre-deployment configuration, wherein said physiomechanical leak abatement component is capable of being positioned at said interior valve region when said prosthetic cardiovascular tissue valve is disposed at said cardiovascular valve structure,

to a post-deployment configuration when said physiomechanical leak abatement component absorbs a first bodily fluid and expands, wherein, when said physiomechanical leak abatement component is disposed in said interior valve region of said prosthetic cardiovascular tissue valve, said outer surface region of said prosthetic cardiovascular tissue valve proximate said interior valve region is placed in intimate contact with host cardiovascular tissue of said cardiovascular valve structure at a cardiovascular structure target position and abates at least one perivalvular leak present at said cardiovascular structure target position during a first perivalvular leak sealing stage,

and wherein, after a first period of time after said outer surface region of said prosthetic cardiovascular tissue valve is placed in said intimate contact with said host cardiovascular tissue of said cardiovascular valve structure at said cardiovascular structure target position, said biological leak sealing component induces remodeling of said outer surface region of said prosthetic cardiovascular tissue valve and regeneration of new cardiovascular tissue at said cardiovascular structure target position, wherein said prosthetic cardiovascular tissue valve further abates said perivalvular leak during a second sealing stage.

2. The perivalvular leak sealing apparatus of claim 1, wherein said first mammalian tissue source comprises a tissue source selected from the group consisting of the small intestine submucosa, urinary bladder submucosa, stomach submucosa and mesothelial tissue.

3. The perivalvular leak sealing apparatus of claim 1, wherein said second mammalian tissue source comprises a tissue source selected from the group consisting of the small intestine submucosa, urinary bladder submucosa, stomach submucosa and mesothelial tissue.

4. The perivalvular leak sealing apparatus of claim 1, wherein said ECM composition further comprises a supplemental biologically active agent.

5. The perivalvular leak sealing apparatus of claim 4, wherein said supplemental biologically active agent comprises a hemostatic agent.

6. The perivalvular leak sealing apparatus of claim 5, wherein said hemostatic agent comprises thrombin.

7. The perivalvular leak sealing apparatus of claim 5, wherein said hemostatic agent comprises fibrinogen.

8. The perivalvular leak sealing apparatus of claim 5, wherein said hemostatic agent is selected from the group comprising fibronectin, plasminogen, aprotinin, α

-2-antiplasmin, α

-2 macroglobulin, α

-1-antitrypsin, epsilon-aminocaproic acid, and tranexamic acid.

9. The perivalvular leak sealing apparatus of claim 4, wherein said supplemental biologically active agent comprises chitosan.

10. The perivalvular leak sealing apparatus of claim 4, wherein said supplemental biologically active agent comprises a growth factor selected from the group consisting of a platelet derived growth factor (PDGF), transforming growth factor-α

(TGF-α

), transforming growth factor beta (TGF-β

), basic fibroblast growth factor (bFGF) and vascular epithelial growth factor (VEGF).